

To,

Date: 10/08/2018

- 1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai – 400 098
- 3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Sub: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company's Letter dated Friday, 03rd August, 2018

With reference to our above letter, this is to inform Exchange that the Board of Directors of the Company at its meeting held today i.e., Friday, the 10th day of August, 2018 at Registered Office, have approved and taken on record the Standalone Un-Audited Financial Results for **Quarter I Ended 30th June, 2018** along with Limited Review Report issued by Statutory Auditors; in compliance with the Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

Further, the Company opts for Submission of Consolidated Audited Financial Results on Yearly basis only as per Regulation 33 of SEBI (LODR) Regulations, 2015.

The meeting commenced at 3.30 PM and concluded at 6.00 PM.

Request you take the same on records.

Thanking you.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)



Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

PART-I				Rs in Lakhs	
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2018					
S.No	Particulars	QUARTER ENDED			Previous Year Ended 31-03-2018
		3 Months ended 30-06-2018	Preceeding 3 months ended 31-03-2018	Corresponding 3 months ended in previous year	
		UnAudited	Audited	UnAudited	Audited
I	Revenue from Operations	30.46	24.05	2.55	61.67
II	Other Income	-	-	-	-
III	Total Revenue (I+II)	30.46	24.05	2.55	61.67
IV	Expenses				
	Cost of Material Consumed	3.11	4.54	-	6.41
	Purchase of Stock-in-trade	-	-	-	-
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-
	Employee benefits expense	34.37	18.41	22.19	87.42
	Finance Costs	-	-	-	-
	Depreciation and Amortisation expense	0.09	0.23	-	0.23
	Professional Charges	10.81	-	-	-
	Other Expenses	44.85	36.62	11.17	69.77
	Total Expenses	93.23	59.80	33.36	163.83
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(62.77)	(35.74)	(30.81)	(102.15)
VI	Exceptional Items				
VII	Profit/(Loss) before tax (V-VI)	(62.77)	(35.74)	(30.81)	(102.15)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(62.77)	(35.74)	(30.81)	(102.15)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(62.77)	(35.74)	(30.81)	(102.15)
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss				
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(62.77)	(35.74)	(30.81)	(102.15)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.53)	(0.34)	(0.30)	(0.96)
	2) Diluted	(0.45)	(0.26)	(0.30)	(0.74)

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)



XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted				
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic 2) Diluted	(0.53) (0.45)	(0.34) (0.26)	(0.30) (0.30)	(0.96) (0.74)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1221.37	1175.87	1025.87	1175.87
XX	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				(142.23)

Notes:

- The format for the Standalone Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016.
- During the Quarter, the Company has converted 4,55,000 Convertible Warrants into Equity Shares on Preferential basis to the Non-Promoters of the Company.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **Friday, 10th August, 2018**.
- The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Section 133, Schedule III (Division II) of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015. The Limited Review was carried out by Statutory Auditors of the Company.
- Ind AS 115 "Revenue from Contracts with Customers", mandatory for reporting for the periods beginning from 01st April, 2018; replaces existing revenue recognition requirements. The application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company. Further, there were no significant adjustments required to the retained earnings as at 01st April, 2018 under the modified retrospective approach.
- As per Regulation 33(3)(b)(i) of SEBI (LODR) Regulations, 2015; the Company opts for submission of Consolidated Audited Financial Results on Yearly basis only.
- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison. The Statement includes the Results for the Quarter and Year Ended 31st March, 2018 as reported in these Standalone Financial Results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the previous financial year.
- The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : 10-08-2018

For DR HABEEBULLAH LIFE SCIENCES LIMITED


K. Krishnam Raju

Executive Chairman (DIN 00874650)



Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India
 Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008. TS. India
 CIN No. : L85110TG1996PLC099198
 Contact No.: 040 - 2970 3333, +91 9030057370
 Email : info@drhlsl.com, peproductsindia@gmail.com
 Website : www.drhlsl.com



N. M. KHATAVKA & CO.

CHARTERED ACCOUNTANTS

Cell : 94488 37388

Tele / Fax : 0836 4265138

Email : nmk1365@gmail.com

nandrajkhataavkar@yahoo.com

LIMITED REVIEW REPORT

(Standalone Un-Audited Financial Results – As per Reg. 33 of SEBI [LODR] Regulations, 2015)

Review Report to DR HABEEBULLAH LIFE SCIENCES LIMITED, Hyderabad.

We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of DR HABEEBULLAH LIFE SCIENCES LIMITED ("the Company") for the Period/Quarter I Ended 30th June, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The preparation of this statement in accordance with the recognition and measurement principles as laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read together with relevant Rules and other Accounting Principles Generally Accepted in India, read together with above referred SEBI Circular is the responsibility of the Company's Management. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS), 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hubli

Date: 10-08-2018

For N.M. Khataavkar & Co.,
Chartered Accountants



N.M. Khataavkar Proprietor
Membership No. 206569
Firm Regd No. 0079395